SCHEMBL6996540

SCHEMBL6996540

O=C1c2ccccc2C(=O)N1CC(O)CN1CCC(Cc2ccccc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.64
PRMT6 Q96LA8 1/20 0.64
DRD4 P21917 5/20 0.59
GRIN2D O15399 1/20 0.59
GRIN3B O60391 1/20 0.59
ADRA1D P25100 1/20 0.59
ADRA1A P35348 1/20 0.59
ADRA1B P35368 1/20 0.59
GRIN1 Q05586 1/20 0.59
GRIN2A Q12879 1/20 0.59
GRIN2B Q13224 1/20 0.59
GRIN2C Q14957 1/20 0.59
GRIN3A Q8TCU5 1/20 0.59
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
ABCB1 P08183 2/20 0.53
ACHE P22303 1/20 0.52
DRD2 P14416 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6992678 0.91 DRD4 (0.56) CARM1PRMT6DRD4GRIN2DGRIN3B
SCHEMBL7985824 0.82 SLC18A3 (0.63)
SCHEMBL7436790 0.82 ADRA1D (0.58) ADRA1DADRA1AADRA1BACHEDRD2
SCHEMBL7245946 0.80 CARM1 (0.71) CARM1PRMT6DRD4GRIN2DGRIN3B
SCHEMBL6995895 0.79 CARM1 (0.69) CARM1PRMT6DRD4GRIN2DGRIN3B
SCHEMBL6986594 0.79 CARM1 (0.69) CARM1PRMT6DRD4GRIN2DGRIN3B
SCHEMBL2680583 0.78 KDM4E (0.56) KMT2AMEN1ABCB1
SCHEMBL7971718 0.78 CCR3 (0.66) DRD4ADRA1DADRA1AADRA1BACHE
SCHEMBL6219793 0.78 DRD2 (0.63) DRD4ADRA1DADRA1AADRA1BACHE
Hydrochloric Acid SCHEMBL7035790 0.78 CARM1 (0.67) CARM1PRMT6DRD4GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642256-B2 Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders WARNER-LAMBERT COMPANY LLC 2003-11-04 US disclosed
EP-1345935-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS Warner-Lambert Company LLC (US) 2003-09-24 EP disclosed
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists KORNBERG BRIAN EDWARD (US) 2003-01-23 US disclosed
WO-2002050070-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists GRIN1, OPRD1, OPRM1 CARM1 683/4885PRMT6 1074/4885DRD4 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.